Quanterix因LucentAD阿尔茨海默氏症血液生物标志物测试CMS价格上涨

2025-09-10 23:56

Shares of Quanterix Corp. are up ~4% in Wednesday morning trading after CMS' recently released preliminary Clinical Lab Fee Schedule listed the company's LucentAD Alzheimer blood biomarker test priced at a maximum reimbursement of $897.
The test is used along with other diagnostic tools to determine if a patient has amyloid pathology consistent with Alzheimer's. It is also used as an aid to determine suitability for drugs used to treat the disease.
The schedule and prices are updated annually with the preliminary schedule out in September and the final out in November.
Leerink Partners' Puneet Souda called the development "a meaningful positive" for Quanterix given reimbursement of blood biomarker tests by CMS remains limited. He added that the company had aimed to crosswalk the LucentAD price to $897.
Souda noted that the Alzheimer's blood diagnostics market remains competitive with CN2 Diagnostics' Precivity and Fujirebio's Lumipulse assays also in the mix. Preclivity's price is $750, while the Lumipulse cerebrospinal fluid assay is $260. The Lumipulse blood-based biomarker test has yet to be priced.
Leerink rates Quanterix at market perform.

More on Quanterix